Study: NCT02763852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 125
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 125
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 125
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.